Nuvalent (NUVL) traded higher Friday as attention shifted to the American Association for Cancer Research (AACR) Annual Meeting 2026, which begins April 17 and runs through April 22 in San Diego. Nuvalent has flagged two AACR poster presentations for zidesamtinib, including a clinical poster focused on a subset of TKI pre-treated ROS1-positive NSCLC patients from the ARROS-1 Phase 1/2 trial and a late-breaking preclinical poster on differentiated brain penetrance and intracranial activity, both scheduled for April 21 (2:00–5:00 p.m. PT). (prnewswire.com)

The AACR updates keep investor focus on whether zidesamtinib can sustain efficacy in later-line ROS1-positive lung cancer patients, including those previously treated with newer ROS1 inhibitors, and whether the compound’s intracranial profile can help address brain metastases—a major clinical differentiator in targeted lung cancer therapy. Any incremental clarity on response durability, resistance coverage, and CNS activity can shift expectations around commercialization potential and competitive positioning heading deeper into 2026. (prnewswire.com)

Nuvalent’s AACR presentations are slated for Tuesday, April 21, 2026, with the meeting underway April 17–22. Traders will also stay focused on the company’s regulatory cadence in 2026 after Nuvalent submitted an NDA on April 7, 2026 for neladalkib in TKI pre-treated advanced ALK-positive NSCLC, which adds another near-term catalyst path alongside zidesamtinib. (prnewswire.com)